UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

AC133+ G0 Cells from Cord Blood Show a High Incidence of Long‐Term Culture–Initiating Cells and a Capacity for More Than 100 Million‐Fold Amplification of Colony‐Forming Cells In Vitro

Stem cells (Dayton, Ohio), 2004, Vol.22 (5), p.704-715

2004

Volltextzugriff (PDF)

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9138-TPS9138

2021

Volltextzugriff (PDF)

Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3588-3588

2020

Volltextzugriff (PDF)

A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2548-2548

2017

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9594-9594

2020

Volltextzugriff (PDF)

Thymoma and thymic carcinoma case series: The Christie Hospital

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20110-e20110

2016

Volltextzugriff (PDF)

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20502-e20502

2017

Volltextzugriff (PDF)

EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants: The Manchester Lung Cancer Group Experience

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18095-e18095

2012

Volltextzugriff (PDF)

Cord Blood G0 CD34+ Cells Have A Thousand‐Fold Higher Capacity For Generating Progenitors In Vitro Than G1 CD34+ Cells

Stem cells (Dayton, Ohio), 2001-11, Vol.19 (6), p.505-513

2001

Volltextzugriff (PDF)

AC133 + G 0 Cells from Cord Blood Show a High Incidence of Long‐Term Culture–Initiating Cells and a Capacity for More Than 100 Million‐Fold Amplification of Colony‐Forming Cells In Vitro

Stem cells (Dayton, Ohio), 2004-09, Vol.22 (5), p.704-715

2004

Volltextzugriff (PDF)

AC133 super(+) G sub(0) Cells from Cord Blood Show a High Incidence of Long-Term Culture-Initiating Cells and a Capacity for More Than 100 Million-Fold Amplification of Colony-Forming Cells In Vitro

Stem cells (Dayton, Ohio), 2004-09, Vol.22 (5), p.704-715

2004

Volltextzugriff (PDF)

Cord Blood G 0 CD34 + Cells Have A Thousand‐Fold Higher Capacity For Generating Progenitors In Vitro Than G 1 CD34 + Cells

Stem cells (Dayton, Ohio), 2001-11, Vol.19 (6), p.505-513

2001

Volltextzugriff (PDF)

Identification, isolation and ex vivo expansion of haemopoietic progenitor and stem cells

Summers, Yvonne J

2004

Volltextzugriff (PDF)

Structural Variation of Chromosomes in Autism Spectrum Disorder

American journal of human genetics, 2008-02, Vol.82 (2), p.477-488

2008

Volltextzugriff (PDF)

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-06, Vol.376 (25), p.2415-2426

2017

Volltextzugriff (PDF)

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-01, Vol.378 (2), p.113-125

2018

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

The New England journal of medicine, 2020-01, Vol.382 (1), p.41-50

2020

Volltextzugriff (PDF)

Tracking the Evolution of Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-06, Vol.376 (22), p.2109-2121

2017

Volltextzugriff (PDF)

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Nature (London), 2017-05, Vol.545 (7655), p.446-451

2017

Volltextzugriff (PDF)

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

Brain (London, England : 1878), 2022-11, Vol.145 (11), p.4097-4107

2022

Volltextzugriff (PDF)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Annals of oncology, 2016-03, Vol.27 (3), p.417-423

2016

Volltextzugriff (PDF)

Alectinib in Resected ALK -Positive Non-Small-Cell Lung Cancer

The New England journal of medicine, 2024-04, Vol.390 (14), p.1265

2024

Volltextzugriff (PDF)

Adenosine Kinase Deficiency Is Associated with Developmental Abnormalities and Reduced Transmethylation

Plant physiology (Bethesda), 2002-03, Vol.128 (3), p.812-821

2002

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(45)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(26)
Humans
(25)
Male
(15)
Female
(13)
Middle Aged
(12)
Aged
(11)
Oncology
(11)
Lung Cancer
(9)
Adult
(8)
Lung Neoplasms - Drug Therapy
(7)
Mutation
(7)
Aged, 80 And Over
(6)
Biological And Medical Sciences
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Carcinoma, Non-Small-Cell Lung - Genetics
(6)
Non-Small Cell Lung Carcinoma
(6)
Antineoplastic Agents - Therapeutic Use
(5)
Carcinoma, Non-Small-Cell Lung - Pathology
(5)
Chemotherapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AC133+ G0 Cells from Cord Blood Show a High Incidence of Long‐Term Culture–Initiating Cells and a Capacity for More Than 100 Million‐Fold Amplification of Colony‐Forming Cells In Vitro

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON)

Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations

A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results

Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC

Thymoma and thymic carcinoma case series: The Christie Hospital

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial

EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants: The Manchester Lung Cancer Group Experience

Cord Blood G0 CD34+ Cells Have A Thousand‐Fold Higher Capacity For Generating Progenitors In Vitro Than G1 CD34+ Cells

AC133 + G 0 Cells from Cord Blood Show a High Incidence of Long‐Term Culture–Initiating Cells and a Capacity for More Than 100 Million‐Fold Amplification of Colony‐Forming Cells In Vitro

AC133 super(+) G sub(0) Cells from Cord Blood Show a High Incidence of Long-Term Culture-Initiating Cells and a Capacity for More Than 100 Million-Fold Amplification of Colony-Forming Cells In Vitro

Cord Blood G 0 CD34 + Cells Have A Thousand‐Fold Higher Capacity For Generating Progenitors In Vitro Than G 1 CD34 + Cells

Identification, isolation and ex vivo expansion of haemopoietic progenitor and stem cells

Structural Variation of Chromosomes in Autism Spectrum Disorder

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Tracking the Evolution of Non–Small-Cell Lung Cancer

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Alectinib in Resected ALK -Positive Non-Small-Cell Lung Cancer

Adenosine Kinase Deficiency Is Associated with Developmental Abnormalities and Reduced Transmethylation

Suchergebnisse filtern